Detailed information for compound 103464

Basic information

Technical information
  • TDR Targets ID: 103464
  • Name: (5Z)-5-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(E)-(phe nylcarbamoylhydrazinylidene)methyl]-3,3a,4,5, 6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoi c acid
  • MW: 385.457 | Formula: C21H27N3O4
  • H donors: 4 H acceptors: 4 LogP: 1.64 Rotable bonds: 9
    Rule of 5 violations (Lipinski): 1
  • SMILES: O=C(Nc1ccccc1)N/N=C/[C@H]1[C@H](O)C[C@H]2[C@@H]1C/C(=C\CCCC(=O)O)/C2
  • InChi: 1S/C21H27N3O4/c25-19-12-15-10-14(6-4-5-9-20(26)27)11-17(15)18(19)13-22-24-21(28)23-16-7-2-1-3-8-16/h1-3,6-8,13,15,17-19,25H,4-5,9-12H2,(H,26,27)(H2,23,24,28)/b14-6-,22-13+/t15-,17-,18+,19+/m0/s1
  • InChiKey: DDBFYGAIHAZCOR-OFCPNAQTSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (5Z)-5-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(E)-(phenylcarbamoylhydrazono)methyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
  • (5Z)-5-[(3aS,4S,5R,6aS)-4-[(E)-[[anilino(oxo)methyl]hydrazono]methyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
  • (5Z)-5-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(E)-(phenylcarbamoylhydrazono)methyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]valeric acid
  • (5Z)-5-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(E)-[[oxo-(phenylamino)methyl]hydrazono]methyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens thromboxane A2 receptor Starlite/ChEMBL No references

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Trypanosoma brucei hypothetical protein, conserved 0.0019 0 0.5
Echinococcus multilocularis SWI:SNF matrix associated 0.0053 1 1
Leishmania major hypothetical protein, conserved 0.0019 0 0.5
Trypanosoma cruzi Zn-finger in Ran binding protein and others/FYVE zinc finger, putative 0.0019 0 0.5
Toxoplasma gondii SWIB/MDM2 domain-containing protein 0.0053 1 1
Leishmania major hypothetical protein, conserved 0.0019 0 0.5
Echinococcus granulosus SWI:SNF matrix associated 0.0053 1 1
Trypanosoma brucei mitochondrial RNA binding complex 1 subunit 0.0019 0 0.5
Leishmania major hypothetical protein, conserved 0.0019 0 0.5
Trypanosoma cruzi mitochondrial RNA binding complex 1 subunit, putative 0.0019 0 0.5
Trypanosoma cruzi hypothetical protein, conserved 0.0019 0 0.5
Trypanosoma cruzi hypothetical protein, conserved 0.0019 0 0.5
Trypanosoma brucei hypothetical protein, conserved 0.0019 0 0.5
Toxoplasma gondii DNA topoisomerase domain-containing protein 0.0053 1 1
Leishmania major hypothetical protein, conserved 0.0019 0 0.5
Echinococcus multilocularis Upstream activation factor subunit UAF30 0.0053 1 1
Loa Loa (eye worm) brahma associated protein 0.0053 1 1
Schistosoma mansoni brg-1 associated factor 0.0053 1 1
Schistosoma mansoni hypothetical protein 0.0053 1 1
Schistosoma mansoni hypothetical protein 0.0053 1 1
Echinococcus multilocularis SWI:SNF matrix associated 0.0053 1 1
Trypanosoma cruzi Zn-finger in Ran binding protein and others, putative 0.0019 0 0.5
Echinococcus granulosus Upstream activation factor subunit UAF30 0.0053 1 1
Loa Loa (eye worm) SWIB/MDM2 domain-containing protein 0.0053 1 1
Trypanosoma brucei Zn-finger in Ran binding protein and others/FYVE zinc finger, putative 0.0019 0 0.5
Echinococcus multilocularis SWI:SNF matrix associated 0.0053 1 1
Trypanosoma cruzi mitochondrial RNA binding complex 1 subunit, putative 0.0019 0 0.5
Trypanosoma cruzi Zn-finger in Ran binding protein and others, putative 0.0019 0 0.5
Leishmania major hypothetical protein, conserved 0.0019 0 0.5
Brugia malayi SWIB/MDM2 domain containing protein 0.0053 1 1
Trypanosoma cruzi WLM domain containing protein, putative 0.0019 0 0.5
Plasmodium vivax hypothetical protein, conserved 0.0053 1 0.5
Plasmodium vivax SWIB/MDM2 domain-containing protein, putative 0.0053 1 0.5
Onchocerca volvulus 0.0053 1 1
Trichomonas vaginalis conserved hypothetical protein 0.0053 1 0.5
Chlamydia trachomatis DNA topoisomerase I 0.0053 1 0.5
Trypanosoma cruzi WLM domain containing protein, putative 0.0019 0 0.5
Chlamydia trachomatis SWIB complex protein 0.0053 1 0.5
Plasmodium falciparum SWIB/MDM2 domain-containing protein 0.0053 1 1
Plasmodium falciparum SWIB/MDM2 domain-containing protein 0.0053 1 1
Schistosoma mansoni hypothetical protein 0.0053 1 1
Trypanosoma cruzi hypothetical protein, conserved 0.0019 0 0.5
Brugia malayi brahma associated protein 60 kDa 0.0053 1 1

Activities

Activity type Activity value Assay description Source Reference
CF (binding) = 1.5 TP receptor affinity, expressed as competition factor (CF) which is the ratio of IC50 of test to IC50 of standard ChEMBL. No reference
CF (binding) = 1.5 TP receptor affinity, expressed as competition factor (CF) which is the ratio of IC50 of test to IC50 of standard ChEMBL. No reference
CF (binding) = 20 TP receptor affinity, expressed as competition factor (CF) which is the ratio of IC50 of test to IC50 of standard ChEMBL. No reference
IC50 (functional) = 0.0000001 M Ability to inhibit blood platelet aggregation of human platelet-rich plasma induced by TP-receptor agonist U 46619 ChEMBL. No reference
IC50 (functional) = 0.0000001 M Ability to inhibit blood platelet aggregation of human platelet-rich plasma induced by TP-receptor agonist U 46619 ChEMBL. No reference
IC50 (functional) = 0.0000017 M Ability to inhibit blood platelet aggregation of human platelet-rich plasma induced by TP-receptor agonist U 46619 ChEMBL. No reference
Relative potency (functional) = 0.17 Antiaggregatory potency of the compound relative to TP-receptor antagonist SQ 29548 ChEMBL. No reference
Relative potency (functional) = 0.005 Antiaggregatory potency of the compound relative to TP-receptor antagonist SQ 29548 ChEMBL. No reference
Relative potency (functional) = 0.17 Antiaggregatory potency of the compound relative to TP-receptor antagonist SQ 29548 ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.